The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

The preclinical studies for AZD5658 focus on evaluating its effects on disease progression in lupus models and assessing inflammatory markers. When can we expect results from the preclinical lupus ...

"Ultimately, we need better diagnostic and prognostic markers in lupus," she said. "There is a lot of research that is ongoing in this space to enable us to develop better tools to diagnosis lupus ...

Blood tests, including but not limited to assays for lupus-related markers, and imaging were also performed at about double the rates seen in controls. No particular type of test, prescription ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...

New research reveals disturbing nightmares and hallucinations may serve as early warning signs of lupus, potentially helping patients receive treatment sooner.

Q4 2024 Earnings Call Transcript March 11, 2025 Exagen Inc. beats earnings expectations. Reported EPS is $-0.2, expectations ...

Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The ...

Greetings and welcome to Exagen Inc fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host ...

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...